Risankizumab-rzaa

Brand names: Skyrizi · Active ingredient: Risankizumab

In short: SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy. SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults and pediatric patients 6 ye

Forms & strengthsSubcutaneous Injection : colorless to yellow, and clear to slightly opalescent solution. SKYRIZI Pen Injection: 150 mg/mL in a single-dose prefilled pen. SKYRIZI Prefilled Syringe Injection: 55 mg/0.37 mL in a single-dose prefilled syringe. …
LabelAbbVie Inc.
Label updatedNov 02, 2026

What is Risankizumab-rzaa used for?

SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy.

SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults and pediatric patients 6 years of age and older.

SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults.

SKYRIZI is indicated for the treatment of moderately to severely active ulcerative colitis in adults.

Risankizumab-rzaa dosage

• For the treatment of moderately to severely active Crohn’s disease and ulcerative colitis, obtain liver enzymes and bilirubin levels prior to initiating treatment with SKYRIZI .

• Consider evaluating patients for tuberculosis (TB) infection prior to initiating treatment with SKYRIZI based on clinical judgement .

• Complete all age-appropriate vaccinations as recommended by current immunization guidelines .

Adults

The recommended dosage for adults is 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter .

Pediatric Patients 6 Years of Age and Older

The recommended dosage for pediatric patients 6 years of age and older is based on body weight and administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter .

Table 1. Recommended Dose of SKYRIZI for Pediatric Patients 6 Years of Age and Older with Moderate-to-Severe Plaque Psoriasis

Body Weight | Recommended Dose

less than 40 kg | 55 mg

40 kg or greater | 150 mg

Adults

The recommended dosage for adult patients is 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter .

SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs).

Pediatric Patients 6 Years of Age and Older

The recommended dosage for pediatric patients 6 years of age and older is based on body weight and administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter .

Table 2.

Recommended Dose of SKYRIZI for Pediatric Patients 6 Years of Age and Older with Active Psoriatic Arthritis

Body Weight | Recommended Dose

less than 40 kg | 55 mg

40 kg or greater | 150 mg

SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs).

Adult

s

Induction

The recommended induction dosage of SKYRIZI is:

• 600 mg administered by intravenous infusion over a period of at least one hour at Week 0, Week 4, and Week 8

or

• 720 mg administered by subcutaneous injection at Week 0, Week 2, Week 4, and Week 8

Maintenance

The recommended maintenance dosage of SKYRIZI is 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Use the lowest effective dosage needed to maintain therapeutic response .

Adult

s

Induction

The recommended induction dosage of SKYRIZI is 1,200 mg administered by intravenous infusion over a period of at least two hours at Week 0, Week 4, and Week 8 .

Maintenance

The recommended maintenance dosage of SKYRIZI is 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Use the lowest effective dosage needed to maintain therapeutic response . …

How to take Risankizumab-rzaa — instructions & advice from the label

Advise patients and/or caregivers to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

Hypersensitivity Reactions

Advise patients to discontinue SKYRIZI and seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions .

Infections

Inform patients that SKYRIZI may lower the ability of their immune system to fight infections. Instruct patients of the importance of communicating any history of infections to the healthcare provider and contacting their healthcare provider if they develop any symptoms of an infection .

Hepatotoxicity

Inform patients that SKYRIZI may cause liver injury, especially during the initial 12 weeks of treatment. Instruct patients to seek immediate medical attention if they experience symptoms suggestive of liver dysfunction (e.g., unexplained rash, nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine)

.

Immunizations

Advise patients that vaccination with live vaccines is not recommended during SKYRIZI treatment and immediately prior to or after SKYRIZI treatment. …

Warnings & precautions

Do not take this medicine if: SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients .

Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately .

SKYRIZI may increase the risk of infections .

Treatment with SKYRIZI should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer SKYRIZI until the infection resolves.

Consider evaluating patients for tuberculosis (TB) infection prior to initiating treatment with SKYRIZI based on clinical judgement. Consider anti-TB therapy prior to initiating SKYRIZI in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Avoid administering SKYRIZI to patients with active TB.

A serious adverse reaction of drug-induced liver injury in conjunction with a rash that required hospitalization was reported in a patient with Crohn’s disease (ALT 54x ULN, AST 30x ULN, and total bilirubin 2.2x ULN) following two 600 mg intravenous doses of SKYRIZI. The liver test abnormalities resolved following administration of steroids. SKYRIZI was subsequently discontinued. …

Risankizumab-rzaa side effects

The following adverse reactions are discussed in other sections of labeling:

Hypersensitivity Reactions

Infections

Tuberculosis

Hepatotoxicity

Because clinical trials are conducted under widely varying conditions, adverse drug reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse Reactions in

Adults with

Plaque Psoriasis

A total of 2234 subjects were treated with SKYRIZI in clinical development trials in plaque psoriasis. Of these, 1208 subjects with psoriasis were exposed to SKYRIZI for at least one year.

Data from placebo- and active-controlled trials were pooled to evaluate the safety of SKYRIZI for up to 16 weeks. In total, 1306 subjects were evaluated in the SKYRIZI 150 mg group.

Table 4 summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher rate in the SKYRIZI group than the placebo group during the 16-week controlled period of pooled clinical trials. …

About this medicine

Risankizumab-rzaa, an interleukin-23 (IL-23) antagonist, is a humanized immunoglobulin G1 (IgG1) monoclonal antibody. Risankizumab-rzaa is produced by recombinant DNA technology in Chinese hamster ovary cells and has an approximate molecular weight of 149 kDa.

SKYRIZI (risankizumab-rzaa) injection

55

mg/

0.37

mL prefilled syringe for subcutaneous use

Each SKYRIZI prefilled syringe contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution. Each syringe delivers 55 mg of risankizumab-rzaa and the inactive ingredients glacial acetic acid (0.02 mg), polysorbate 20 (0.07 mg), sodium acetate (0.28 mg), trehalose (23.4 mg), and Water for Injection, USP. The pH is 5.7.

SKYRIZI (risankizumab-rzaa) injection 150 mg/mL prefilled syringe or prefilled pen for subcutaneous use

Each SKYRIZI prefilled pen or prefilled syringe contains a sterile, preservative-free, colorless to yellow, and clear to slightly opalescent solution. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 7148c8eb-b39e-e20a-6494-a6df82392858. Read the full official label on DailyMed.

Related medicines

Doxycycline Adalimumab Ketoconazole Levocetirizine Cyclosporine Tretinoin Brimonidine Dupilumab